Strengthening Antimalarial Quality Assurance System in Nigeria: A Comprehensive Strategy for Ensuring the Safety and Effectiveness of Medications
Authors
Issue Date
Type
Language
Keywords
Alternative Title
Abstract
Nigeria's public health is seriously threatened by the widespread use of substandard and
counterfeit antimalarial medications, which compromise treatment effectiveness, increase the
burden of disease, and compromise patient outcomes. This research uses a thorough and
multidisciplinary strategy to strengthen Nigeria's antimalarial quality assurance system in
response to this urgent challenge. This research analyses the underlying reasons for
medication quality oversights, assesses current regulatory frameworks, and pinpoints
important areas for intervention by utilizing regulatory analysis, stakeholder interaction, and
empirical investigations.
Deficient regulatory supervision, vulnerabilities in the pharmaceutical supply chain, and low
awareness among consumers are the main causes of the spread of inferior antimalarial
medications, according to the research. The study cultivates cooperative partnerships with
regulatory bodies, healthcare providers, pharmaceutical manufacturers, and community
stakeholders to improve oversight, compliance, and transparency in the pharmaceutical
supply chain.
The research produces practical insights and evidence-based suggestions for enhancing
Nigeria's antimalarial quality assurance system using surveys, interviews, and data analysis.
These ideas, which aim to reduce the dangers associated with poor medicine delivery and
protect patient safety, include regulatory reforms, capacity-building programs, technology
driven solutions, and community empowerment techniques.
Furthermore, by highlighting the perspectives and experiences of those impacted by
pharmaceutical quality lapses, the study emphasizes the significance of patient-centred
approaches in developing efficient interventions and regulations. A future in which every
person has access to safe, efficient, and high-quality antimalarial drugs can be achieved by
stakeholders working together by placing a priority on patient safety and well-being. This
would advance the larger objective of eradicating malaria and improving health outcomes for
all in Nigeria.